The SARS-CoV-2 host cell membrane fusion protein TMPRSS2 is a tumor suppressor and its downregulation correlates with increased antitumor immunity and immunotherapy response in lung adenocarcinoma

Zhixian Liu,Zhilan Zhang,Qiushi Feng,Xiaosheng Wang

DOI: https://doi.org/10.1101/2021.06.30.450490

2021-01-01

bioRxiv

Abstract:Background TMPRSS2 is a host cell membrane fusion protein for SARS-CoV-2 invading human host cells. It also has an association with cancer, particularly prostate cancer. However, its association with lung cancer remains insufficiently explored. Thus, an in-depth investigation into the association between TMPRSS2 and lung cancer is significant, considering that lung cancer is the leading cause of cancer death and that the lungs are the primary organ SARS-CoV-2 attacks. Methods Using five lung adenocarcinoma (LUAD) genomics datasets, we explored associations between TMPRSS2 expression and immune signatures, cancer-associated pathways, tumor progression phenotypes, and clinical prognosis in LUAD by the bioinformatics approach. Furthermore, we validated the findings from the bioinformatics analysis by performing in vitro experiments with the human LUAD cell line A549 and in vivo experiments with mouse tumor models. We also validated our findings in LUAD patients from Jiangsu Cancer Hospital, China. Results TMPRSS2 expression levels were negatively correlated with the enrichment levels of CD8+ T and NK cells and immune cytolytic activity in LUAD, which represent antitumor immune signatures. Meanwhile, TMPRSS2 expression levels were negatively correlated with the enrichment levels of CD4+ regulatory T cells and myeloid-derived suppressor cells and PD-L1 expression levels in LUAD, which represent antitumor immunosuppressive signatures. However, TMPRSS2 expression levels showed a significant positive correlation with the ratios of immune-stimulatory/immune-inhibitory signatures (CD8+ T cells/PD-L1) in LUAD. It indicated that TMPRSS2 levels had a stronger negative correlation with immune-inhibitory signatures than with immune-stimulatory signatures. TMPRSS2 downregulation correlated with elevated activities of many oncogenic pathways in LUAD, including cell cycle, mismatch repair, p53, and extracellular matrix (ECM) signaling. TMPRSS2 downregulation correlated with increased proliferation, stemness, genomic instability, tumor advancement, and worse survival in LUAD. In vitro and in vivo experiments validated the association of TMPRSS2 deficiency with increased tumor cell proliferation and invasion and antitumor immunity in LUAD. Moreover, in vivo experiments demonstrated that TMPRSS2 -knockdown tumors were more sensitive to BMS-1, an inhibitor of PD-1/PD-L1. Conclusions TMPRSS2 is a tumor suppressor, while its downregulation is a positive biomarker of immunotherapy in LUAD. Our data provide a connection between lung cancer and pneumonia caused by SARS-CoV-2 infection. ### Competing Interest Statement The authors have declared no competing interest. * ACE2 : angiotensin-converting enzyme 2 CCK-8 : the Cell Counting Kit-8 DAPI : 4’,6- diamidino-2-phenylindole DDR : DNA damage repair DFS : disease-free survival ECM : extracellular matrix FC : fold change FDR : false discovery rate GO : gene ontology GSEA : gene set enrichment analysis HRD : Homologous recombination deficiency ICIs : immune checkpoint inhibitors ITH : intratumor heterogeneity LUAD : lung adenocarcinoma LUSC : lung squamous cell carcinoma MDSCs : myeloid-derived suppressor cells OS : overall survival PI : proximal-inflammatory PP : proximal-proliferative RT-PCR : Real-Time PCR S : spike glycoprotein SARS-CoV-2 : severe acute respiratory syndrome coronavirus 2 siRNA : small interfering RNA ssGSEA : single-sample gene-set enrichment analysis TCGA : The Cancer Genome Atlas TILs : tumor-infiltrating lymphocytes TMB : tumor mutation burden TMPRSS2 : transmembrane protease serine 2 TRU : terminal respiratory unit WGCNA : weighted gene co-expression network analysis